Luke Ralston, a biomedical engineer and scientific reviewer at the FDA, has emphasised the need for transparency in AI regulation. The two main issues hampering the regulation are performance drift and data generalisation. Ralston stated that AI companies need to start monitoring and tracking the performance of their products once deployed and they also need to expand its representative data to cover more than just the demographics.
A Tale of Two States: The 2026 Cybersecurity Paradox
The cyber threat outlooks from CIOs and CISOs at the NASCIO Midyear Conference in Philadelphia ranged from the good to the bad to the ugly
